Podcast: Download (Duration: 1:36 — 1.5MB) | Embed

Subscribe: Apple Podcasts | Spotify | RSS

An analysis of over 160,000 non-valvular atrial fibrillation patients has found that Eliquis, a direct oral anticoagulant or DOAC, had lower rates of major bleeding and stroke/systemic embolism in a series of head-to-head comparisons among Eliquis, Pradaxa, and Xarelto.

– Eliquis has a 17% lower rate of stroke/systemic embolism and a 46% lower rate of major bleeding compared with Xarelto.

– Eliquis has a 31% lower rate of stroke/systemic embolism and a 23% lower rate of major bleeding compared with Pradaxa.

There is a significant safety advantage that DOAC’s like Eliquis have over warfarin, especially in regards to intracranial bleeding.

Resource:
https://www.ahajournals.org/doi/10.1161/STROKEAHA.118.020232

Related Episodes

• • Health & Wellness
  • Medical

  Catch-up Sleep
• • Health & Wellness
  • Medical
  • Pharmaceuticals

  Hydroxychloroquine Lowers COVID-19 Mortality